HUTCHMED (China) Limited (HCM)

HUTCHMED (China) has announced that Chief Executive Officer Dr Weiguo Su will take a leave of absence due to health reasons. The Board has appointed Johnny Cheng, the company’s Chief

HUTCHMED has completed patient enrollment for its Phase III SANOVO trial evaluating ORPATHYS® (savolitinib) with TAGRISSO® (osimertinib) as a first-line treatment for certain EGFR-mutated, MET-overexpressed non-small cell lung cancer patients.

HUTCHMED (China) Limited is set to unveil groundbreaking data on key cancer therapies at the 2025 ASCO Annual Meeting, highlighting promising advancements in NSCLC and solid tumors.

HUTCHMED has successfully completed patient enrollment for a Phase II trial of savolitinib, targeting gastric cancer patients with MET amplification.